During the past decade, Dipartimento di Neuroscienze, conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dipartimento di Neuroscienze," are "Alzheimer Disease" (2 trials) and "Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Dipartimento di Neuroscienze," in a lesser frequency.

Most popular intervention types in "Dipartimento di Neuroscienze," are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Bapineuzumab 0.5 mg/kg" (1 trials), "Cladribine" (1 trials), "Placebo" (1 trials), "Rebif® new formulation (RNF)" (1 trials) and "bapineuzumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dipartimento di Neuroscienze," are 3 trials for "All" genders.

Currently, there are NaN active trials in "Dipartimento di Neuroscienze,". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dipartimento di Neuroscienze,, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Dipartimento di Neuroscienze,, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".